Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis
Background & Aims Antibodies (Abs) to soluble liver antigen/liver pancreas (anti‐SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently been attributed to their frequent co‐expression with Abs against Ro52 (...
Gespeichert in:
| Veröffentlicht in: | Liver international 2015-02, Vol.35 (2), p.660-672 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 2 |
| container_start_page | 660 |
| container_title | Liver international |
| container_volume | 35 |
| creator | Zachou, Kalliopi Gampeta, Stella Gatselis, Nikolaos K. Oikonomou, Katerina Goulis, John Manoussakis, Menelaos N. Renaudineau, Yves Bogdanos, Dimitrios P. Dalekos, George N. |
| description | Background & Aims
Antibodies (Abs) to soluble liver antigen/liver pancreas (anti‐SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently been attributed to their frequent co‐expression with Abs against Ro52 (anti‐Ro52). To assess the clinical significance of anti‐SLA/LP Abs alone or in combination with anti‐Ro52 in AIH patients and determine the immunodominant Ro52 epitopes according to the anti‐SLA/LP status.
Methods
Twenty‐three anti‐SLA/LP‐positive and 106 anti‐SLA/LP‐negative AIH patients were included. Anti‐SLA/LP were determined by ELISA using recombinant antigen, and confirmed by immunoblot using cytosolic rat liver fraction or HuH‐7 extract. Anti‐Ro52 Abs were determined by ELISA using recombinant antigen. Epitope mapping was assessed by ELISA using overlapping peptides covering the whole Ro52 protein in 26 AIH patients and 12 patients with Sjögren's syndrome.
Results
Anti‐SLA/LP positivity was not associated with the clinical, laboratory or histological characteristics of AIH patients. Treatment response, corticosteroid withdrawal, relapse after stopping treatment and outcome, were not associated with the presence of anti‐SLA/LP, anti‐Ro52 or double reactivity. Moreover, Ro52 epitope mapping revealed new epitopes unique for AIH and independent from anti‐SLA/LP positivity.
Conclusions
Neither anti‐SLA/LP nor anti‐Ro52 Abs or their combination could specify a distinct group of AIH patients in terms of clinical characteristics, treatment response and outcome. Further studies are needed to clarify whether the newly discovered immunodominant epitopes of Ro52 antigen which were associated specifically with AIH have any clinical or pathogenetic significance in AIH. |
| doi_str_mv | 10.1111/liv.12658 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01068348v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652404268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4678-fee353fb98aaa39ffaa2511dd52fb64307c4c31f33d3c25d2e5ddc60d209abf3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EoqXtghdAWcIiHV8zyXKooK2UQkWrlp3l-KI5kMTT2GmZB-C9cZhpJBZ44yP7-z_p6EfoLcGnJJ1FC4-nhBaifIEOCV-WOaOMvJxnyg7QmxB-YEyqSpDX6IAKQhin-BD9XvUR8pt6taivM9X63mZ-yKDPtO8a6FUE32dPENeZmsBvXtA0mcxBIsPGanCgIW4z7_4hIjTegA2TapMsto9h7xmjh64bU35tp68I4Ri9cqoN9mR_H6Hbz59uzy7y-uv55dmqzjUv0irOWiaYa6pSKcUq55SaNjFGUNcUnOGl5poRx5hhmgpDrTBGF9hQXKnGsSP0Yaddq1ZuBujUsJVegbxY1XJ6wwQXJePlI0ns-x27GfzDaEOUHQRt21b11o9BkkJQjjlN_KzVgw9hsG52EyyngmQqSP4tKLHv9tqx6ayZyedGErDYAU_Q2u3_TbK-vHtW5rsEhGh_zQk1_JTFki2FvP9yLit295FfX13J7-wPhByp1A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652404268</pqid></control><display><type>article</type><title>Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zachou, Kalliopi ; Gampeta, Stella ; Gatselis, Nikolaos K. ; Oikonomou, Katerina ; Goulis, John ; Manoussakis, Menelaos N. ; Renaudineau, Yves ; Bogdanos, Dimitrios P. ; Dalekos, George N.</creator><creatorcontrib>Zachou, Kalliopi ; Gampeta, Stella ; Gatselis, Nikolaos K. ; Oikonomou, Katerina ; Goulis, John ; Manoussakis, Menelaos N. ; Renaudineau, Yves ; Bogdanos, Dimitrios P. ; Dalekos, George N.</creatorcontrib><description>Background & Aims
Antibodies (Abs) to soluble liver antigen/liver pancreas (anti‐SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently been attributed to their frequent co‐expression with Abs against Ro52 (anti‐Ro52). To assess the clinical significance of anti‐SLA/LP Abs alone or in combination with anti‐Ro52 in AIH patients and determine the immunodominant Ro52 epitopes according to the anti‐SLA/LP status.
Methods
Twenty‐three anti‐SLA/LP‐positive and 106 anti‐SLA/LP‐negative AIH patients were included. Anti‐SLA/LP were determined by ELISA using recombinant antigen, and confirmed by immunoblot using cytosolic rat liver fraction or HuH‐7 extract. Anti‐Ro52 Abs were determined by ELISA using recombinant antigen. Epitope mapping was assessed by ELISA using overlapping peptides covering the whole Ro52 protein in 26 AIH patients and 12 patients with Sjögren's syndrome.
Results
Anti‐SLA/LP positivity was not associated with the clinical, laboratory or histological characteristics of AIH patients. Treatment response, corticosteroid withdrawal, relapse after stopping treatment and outcome, were not associated with the presence of anti‐SLA/LP, anti‐Ro52 or double reactivity. Moreover, Ro52 epitope mapping revealed new epitopes unique for AIH and independent from anti‐SLA/LP positivity.
Conclusions
Neither anti‐SLA/LP nor anti‐Ro52 Abs or their combination could specify a distinct group of AIH patients in terms of clinical characteristics, treatment response and outcome. Further studies are needed to clarify whether the newly discovered immunodominant epitopes of Ro52 antigen which were associated specifically with AIH have any clinical or pathogenetic significance in AIH.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12658</identifier><identifier>PMID: 25113420</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>anti-Ro52 antibodies ; anti-SLA/LP antibodies ; Autoantibodies - blood ; Autoantigens - blood ; Autoantigens - immunology ; autoimmune hepatitis ; Biomarkers - blood ; Enzyme-Linked Immunosorbent Assay ; Epitope Mapping ; Greece ; Hepatitis, Autoimmune - blood ; Hepatitis, Autoimmune - classification ; Hepatitis, Autoimmune - immunology ; Humans ; Immunology ; Kaplan-Meier Estimate ; Life Sciences ; Mycophenolic Acid - analogs & derivatives ; Oligonucleotides ; Polymerase Chain Reaction ; Ribonucleoproteins - blood ; Ribonucleoproteins - immunology ; Sjögren's syndrome</subject><ispartof>Liver international, 2015-02, Vol.35 (2), p.660-672</ispartof><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4678-fee353fb98aaa39ffaa2511dd52fb64307c4c31f33d3c25d2e5ddc60d209abf3</citedby><cites>FETCH-LOGICAL-c4678-fee353fb98aaa39ffaa2511dd52fb64307c4c31f33d3c25d2e5ddc60d209abf3</cites><orcidid>0000-0001-5098-5002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12658$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12658$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25113420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-brest.fr/hal-01068348$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Zachou, Kalliopi</creatorcontrib><creatorcontrib>Gampeta, Stella</creatorcontrib><creatorcontrib>Gatselis, Nikolaos K.</creatorcontrib><creatorcontrib>Oikonomou, Katerina</creatorcontrib><creatorcontrib>Goulis, John</creatorcontrib><creatorcontrib>Manoussakis, Menelaos N.</creatorcontrib><creatorcontrib>Renaudineau, Yves</creatorcontrib><creatorcontrib>Bogdanos, Dimitrios P.</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><title>Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background & Aims
Antibodies (Abs) to soluble liver antigen/liver pancreas (anti‐SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently been attributed to their frequent co‐expression with Abs against Ro52 (anti‐Ro52). To assess the clinical significance of anti‐SLA/LP Abs alone or in combination with anti‐Ro52 in AIH patients and determine the immunodominant Ro52 epitopes according to the anti‐SLA/LP status.
Methods
Twenty‐three anti‐SLA/LP‐positive and 106 anti‐SLA/LP‐negative AIH patients were included. Anti‐SLA/LP were determined by ELISA using recombinant antigen, and confirmed by immunoblot using cytosolic rat liver fraction or HuH‐7 extract. Anti‐Ro52 Abs were determined by ELISA using recombinant antigen. Epitope mapping was assessed by ELISA using overlapping peptides covering the whole Ro52 protein in 26 AIH patients and 12 patients with Sjögren's syndrome.
Results
Anti‐SLA/LP positivity was not associated with the clinical, laboratory or histological characteristics of AIH patients. Treatment response, corticosteroid withdrawal, relapse after stopping treatment and outcome, were not associated with the presence of anti‐SLA/LP, anti‐Ro52 or double reactivity. Moreover, Ro52 epitope mapping revealed new epitopes unique for AIH and independent from anti‐SLA/LP positivity.
Conclusions
Neither anti‐SLA/LP nor anti‐Ro52 Abs or their combination could specify a distinct group of AIH patients in terms of clinical characteristics, treatment response and outcome. Further studies are needed to clarify whether the newly discovered immunodominant epitopes of Ro52 antigen which were associated specifically with AIH have any clinical or pathogenetic significance in AIH.</description><subject>anti-Ro52 antibodies</subject><subject>anti-SLA/LP antibodies</subject><subject>Autoantibodies - blood</subject><subject>Autoantigens - blood</subject><subject>Autoantigens - immunology</subject><subject>autoimmune hepatitis</subject><subject>Biomarkers - blood</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epitope Mapping</subject><subject>Greece</subject><subject>Hepatitis, Autoimmune - blood</subject><subject>Hepatitis, Autoimmune - classification</subject><subject>Hepatitis, Autoimmune - immunology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Oligonucleotides</subject><subject>Polymerase Chain Reaction</subject><subject>Ribonucleoproteins - blood</subject><subject>Ribonucleoproteins - immunology</subject><subject>Sjögren's syndrome</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EoqXtghdAWcIiHV8zyXKooK2UQkWrlp3l-KI5kMTT2GmZB-C9cZhpJBZ44yP7-z_p6EfoLcGnJJ1FC4-nhBaifIEOCV-WOaOMvJxnyg7QmxB-YEyqSpDX6IAKQhin-BD9XvUR8pt6taivM9X63mZ-yKDPtO8a6FUE32dPENeZmsBvXtA0mcxBIsPGanCgIW4z7_4hIjTegA2TapMsto9h7xmjh64bU35tp68I4Ri9cqoN9mR_H6Hbz59uzy7y-uv55dmqzjUv0irOWiaYa6pSKcUq55SaNjFGUNcUnOGl5poRx5hhmgpDrTBGF9hQXKnGsSP0Yaddq1ZuBujUsJVegbxY1XJ6wwQXJePlI0ns-x27GfzDaEOUHQRt21b11o9BkkJQjjlN_KzVgw9hsG52EyyngmQqSP4tKLHv9tqx6ayZyedGErDYAU_Q2u3_TbK-vHtW5rsEhGh_zQk1_JTFki2FvP9yLit295FfX13J7-wPhByp1A</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Zachou, Kalliopi</creator><creator>Gampeta, Stella</creator><creator>Gatselis, Nikolaos K.</creator><creator>Oikonomou, Katerina</creator><creator>Goulis, John</creator><creator>Manoussakis, Menelaos N.</creator><creator>Renaudineau, Yves</creator><creator>Bogdanos, Dimitrios P.</creator><creator>Dalekos, George N.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-5098-5002</orcidid></search><sort><creationdate>201502</creationdate><title>Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis</title><author>Zachou, Kalliopi ; Gampeta, Stella ; Gatselis, Nikolaos K. ; Oikonomou, Katerina ; Goulis, John ; Manoussakis, Menelaos N. ; Renaudineau, Yves ; Bogdanos, Dimitrios P. ; Dalekos, George N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4678-fee353fb98aaa39ffaa2511dd52fb64307c4c31f33d3c25d2e5ddc60d209abf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>anti-Ro52 antibodies</topic><topic>anti-SLA/LP antibodies</topic><topic>Autoantibodies - blood</topic><topic>Autoantigens - blood</topic><topic>Autoantigens - immunology</topic><topic>autoimmune hepatitis</topic><topic>Biomarkers - blood</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epitope Mapping</topic><topic>Greece</topic><topic>Hepatitis, Autoimmune - blood</topic><topic>Hepatitis, Autoimmune - classification</topic><topic>Hepatitis, Autoimmune - immunology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Oligonucleotides</topic><topic>Polymerase Chain Reaction</topic><topic>Ribonucleoproteins - blood</topic><topic>Ribonucleoproteins - immunology</topic><topic>Sjögren's syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zachou, Kalliopi</creatorcontrib><creatorcontrib>Gampeta, Stella</creatorcontrib><creatorcontrib>Gatselis, Nikolaos K.</creatorcontrib><creatorcontrib>Oikonomou, Katerina</creatorcontrib><creatorcontrib>Goulis, John</creatorcontrib><creatorcontrib>Manoussakis, Menelaos N.</creatorcontrib><creatorcontrib>Renaudineau, Yves</creatorcontrib><creatorcontrib>Bogdanos, Dimitrios P.</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zachou, Kalliopi</au><au>Gampeta, Stella</au><au>Gatselis, Nikolaos K.</au><au>Oikonomou, Katerina</au><au>Goulis, John</au><au>Manoussakis, Menelaos N.</au><au>Renaudineau, Yves</au><au>Bogdanos, Dimitrios P.</au><au>Dalekos, George N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2015-02</date><risdate>2015</risdate><volume>35</volume><issue>2</issue><spage>660</spage><epage>672</epage><pages>660-672</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
Antibodies (Abs) to soluble liver antigen/liver pancreas (anti‐SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently been attributed to their frequent co‐expression with Abs against Ro52 (anti‐Ro52). To assess the clinical significance of anti‐SLA/LP Abs alone or in combination with anti‐Ro52 in AIH patients and determine the immunodominant Ro52 epitopes according to the anti‐SLA/LP status.
Methods
Twenty‐three anti‐SLA/LP‐positive and 106 anti‐SLA/LP‐negative AIH patients were included. Anti‐SLA/LP were determined by ELISA using recombinant antigen, and confirmed by immunoblot using cytosolic rat liver fraction or HuH‐7 extract. Anti‐Ro52 Abs were determined by ELISA using recombinant antigen. Epitope mapping was assessed by ELISA using overlapping peptides covering the whole Ro52 protein in 26 AIH patients and 12 patients with Sjögren's syndrome.
Results
Anti‐SLA/LP positivity was not associated with the clinical, laboratory or histological characteristics of AIH patients. Treatment response, corticosteroid withdrawal, relapse after stopping treatment and outcome, were not associated with the presence of anti‐SLA/LP, anti‐Ro52 or double reactivity. Moreover, Ro52 epitope mapping revealed new epitopes unique for AIH and independent from anti‐SLA/LP positivity.
Conclusions
Neither anti‐SLA/LP nor anti‐Ro52 Abs or their combination could specify a distinct group of AIH patients in terms of clinical characteristics, treatment response and outcome. Further studies are needed to clarify whether the newly discovered immunodominant epitopes of Ro52 antigen which were associated specifically with AIH have any clinical or pathogenetic significance in AIH.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25113420</pmid><doi>10.1111/liv.12658</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-5098-5002</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2015-02, Vol.35 (2), p.660-672 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01068348v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | anti-Ro52 antibodies anti-SLA/LP antibodies Autoantibodies - blood Autoantigens - blood Autoantigens - immunology autoimmune hepatitis Biomarkers - blood Enzyme-Linked Immunosorbent Assay Epitope Mapping Greece Hepatitis, Autoimmune - blood Hepatitis, Autoimmune - classification Hepatitis, Autoimmune - immunology Humans Immunology Kaplan-Meier Estimate Life Sciences Mycophenolic Acid - analogs & derivatives Oligonucleotides Polymerase Chain Reaction Ribonucleoproteins - blood Ribonucleoproteins - immunology Sjögren's syndrome |
| title | Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-SLA/LP%20alone%20or%20in%20combination%20with%20anti-Ro52%20and%20fine%20specificity%20of%20anti-Ro52%20antibodies%20in%20patients%20with%20autoimmune%20hepatitis&rft.jtitle=Liver%20international&rft.au=Zachou,%20Kalliopi&rft.date=2015-02&rft.volume=35&rft.issue=2&rft.spage=660&rft.epage=672&rft.pages=660-672&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12658&rft_dat=%3Cproquest_hal_p%3E1652404268%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652404268&rft_id=info:pmid/25113420&rfr_iscdi=true |